Cemag Care Launches Haima: A Non-Hormonal Option for Heavy Menstrual Bleeding

Managing heavy menstrual bleeding—clinically known as menorrhagia—often involves a choice between hormonal treatments or prescription-only medications. The introduction of HAIMA® 1000 mg by CEMAG Care provides a new, non-hormonal alternative designed to fit into modern lifestyles while reducing debilitating bleeding.

What is Haima?

Haima is a medicinal product containing the active substance tranexamic acid. It belongs to a therapeutic class called antifibrinolytics. Unlike many common treatments for heavy periods, Haima does not apply hormones to regulate bleeding, making it a distinct option for women seeking non-hormonal intervention.

The medication is formulated as 1000 mg coated granules delivered in sachets. These granules are intended for oral administration and should be taken without chewing.

Dosage and Administration

To ensure efficacy and safety, Haima must be used according to specific guidelines. Based on product information, the recommended protocol is as follows:

• Dosage: One sachet taken three times per day.
• Duration: The treatment should be used for a maximum of four days.
• Packaging: Each box contains 12 sachets.

Market Availability and Strategic Expansion

CEMAG Care is aggressively expanding the reach of Haima (and its related formulation, NEXAG®) across Europe to improve access to menstrual health solutions.

European Distribution

In France, Haima is available as an over-the-counter (OTC) option. It is categorized as a List 1 medication and is not reimbursed. While a similar prescription drug called Exacyl exists and is reimbursed, Haima offers a different point of access for patients.

Central and Eastern Europe

To broaden its impact, CEMAG Care has signed a distribution agreement with MagnaPharm Group. This partnership brings Haima to three key markets:

• Poland
• Romania
• Hungary

Critical Safety Considerations

While Haima provides a convenient solution for managing symptoms, medical experts highlight several important cautions regarding self-treatment:

The Risk of Delayed Diagnosis

Because Haima is available without a prescription in some markets, there is a concern that women may use it to treat symptoms without identifying the root cause of their heavy bleeding. Self-treating may delay the diagnosis of underlying medical conditions that require specific clinical intervention.

Blood Clotting Concerns

As an antifibrinolytic, tranexamic acid affects how the body clots. Experts warn that this can raise safety concerns regarding the potential for blood clots, meaning professional medical consultation is advised before starting the medication.

Key Takeaways

• Active Ingredient: Tranexamic acid (1000 mg).
• Primary Use: Management of heavy menstrual bleeding (menorrhagia).
• Non-Hormonal: Provides an alternative for those avoiding hormonal therapies.
• Administration: 1 sachet, 3 times daily, for up to 4 days.
• Availability: OTC in France; distributed via MagnaPharm in Poland, Romania, and Hungary.

Frequently Asked Questions

Is Haima a hormonal medication?

No, Haima is a non-hormonal treatment. It uses tranexamic acid, an antifibrinolytic, to reduce bleeding.

Can I chew the Haima granules?

No, the coated granules should be taken orally without being chewed.

Is Haima reimbursed in France?

No, Haima is not reimbursed and is listed as a List 1 medication.

Conclusion

The launch of Haima represents a strategic shift toward providing more accessible, non-hormonal options for women struggling with menorrhagia. By expanding into Central and Eastern Europe through MagnaPharm Group, CEMAG Care is positioning the product as a modern solution for menstrual health. However, the transition to over-the-counter availability underscores the importance of balanced self-care; patients should remain vigilant about the risks of blood clots and the necessity of professional diagnosis for chronic heavy bleeding.